Biomoda, Inc. is a cancer diagnostics company focused on creating a cost-effective, non-invasive, accurate and reproducible diagnostic tests for the early detection of cancer. http://www.biomoda.com/ http://www.biomoda.com/wp-content/uploads/New-LOGO.jpg http://www.biomoda.com/ 144 35 The Chief Executive Officer of cancer diagnostics company Biomoda, Inc. discussed top-line results of the company's pilot clinical trial of the CyPath® diagnostic for lung cancer on nationally syndicated business radio talk shows airing on the Business Talk Radio Network and the Radio America Network as well as Money Matters Radio in the Boston market. http://www.biomoda.com/news/biomoda-ceo-discusses-top-line-results-on-business-radio/ Cancer diagnostics company Biomoda, Inc. today announced that LifeTech Capital has updated its independent research coverage on Biomoda based on top-line results of the pilot clinical trial of Biomoda's CyPath® diagnostic assay for lung cancer. http://www.biomoda.com/news/lifetech-capital-updates-research-coverage-of-biomoda-2/ Cancer diagnostics company Biomoda, Inc. today announced the signing of a Memorandum of Understanding with the University of Texas Health Science Center at San Antonio to collaborate on research to optimize the CyPath® diagnostic assay for lung cancer. http://www.biomoda.com/news/biomoda-collaborates-with-ut-health-science-center-at-san-antonio/ Cancer diagnostics company Biomoda, Inc. today announced top-line results of its pilot study for lung cancer which shows highly significant evidence of CyPath®'s ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner. http://www.biomoda.com/news/biomoda-top-line-results-show-significant-new-biomarker-for-lung-cancer/ In the monthly President's Column posted Monday, March 14, at, cancer diagnostics company Biomoda, Inc. reported on its optimization research for the CyPath® assay now that the pilot clinical study has been completed. http://www.biomoda.com/news/biomoda-focuses-on-optimizing-cypath%C2%AE-diagnostic-assay/ Cancer diagnostics company Biomoda, Inc. today announced that it has been accepted as an associate member of the Early Detection Research Network (EDRN), an initiative of the National Cancer Institute (NCI) focused on the development of molecular technologies for the screening, early diagnosis and target-based treatment of cancer. http://www.biomoda.com/news/joins-national-cancer-institute%E2%80%99s-early-detection-research-network/ Cancer diagnostics company Biomoda, Inc. today announced that it has completed patient enrollment and sample collection for the pilot study to determine the clinical sensitivity and specificity of its CyPath® diagnostic assay for the early detection of lung cancer. http://www.biomoda.com/news/biomoda-completes-patient-enrollment-and-sample-collection-for-pilot-study/ This is the third monthly Question and Answer column by John Cousins, President and Chief Executive Officer. http://www.biomoda.com/presidents-column/